US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Keen Vision Acquisition Corp.

11.30

+0.08000.71%

Volume:500.00

Turnover:5.65K

Market Cap:176.60M

PE:- -

High:11.30

Open:11.30

Low:11.30

Close:11.22

Loading ...

Overview Company News Filings

Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

Medera Completes Patient Dosing for Heart Failure Treatment

Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera, Inc. to Participate in Two Upcoming Investor Conferences

Keen Vision Acquisition Extends Business Combination Deadline

MT Newswires Live

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KVACU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KVACU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KVACU\",,,,,undefined,":{"symbol":"KVACU","market":"US","secType":"STK","nameCN":"Keen Vision Acquisition Corp.","latestPrice":11.3,"timestamp":1745427930360,"preClose":11.22,"halted":0,"volume":500,"delay":0,"floatShares":15013374,"shares":15628575,"eps":0,"marketStatus":"Trading","change":0.08,"latestTime":"04-23 14:23:05 EDT","open":11.3,"high":11.3,"low":11.3,"amount":5650,"amplitude":0,"askPrice":11.79,"askSize":100,"bidPrice":11.3,"bidSize":24500,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745438400000},"marketStatusCode":2,"adr":0,"listingDate":1690257600000,"exchange":"NASDAQ","adjPreClose":11.22,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KVACU\",,,,,undefined,":{"symbol":"KVACU","floatShares":15013374,"roa":"--","roe":"--","lyrEps":-0.000185,"shares":15628575,"dividePrice":0,"high":11.3,"amplitude":0,"preClose":11.22,"low":11.3,"week52Low":10.46,"pbRate":"-42.06","week52High":13.72,"institutionHeld":0,"latestPrice":11.3,"committee":0.99187,"eps":0,"divideRate":0,"volume":500,"delay":0,"ttmEps":0,"open":11.3,"prevYearClose":10.99,"prevWeekClose":11.22,"prevMonthClose":11.22,"prevQuarterClose":11.22,"fiveDayClose":11.22,"twentyDayClose":11.2,"sixtyDayClose":11.1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KVACU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524900451","title":"Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2524900451","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524900451?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:00","pubTimestamp":1743508800,"startTime":"0","endTime":"0","summary":"BOSTON, April 01, 2025  -- Medera Inc. , a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that updated results from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial investigating SRD-002, a one-time gene therapy treatment delivered through a proprietary minimally invasive intracoronary infusion methodology, were presented at the 2025 HFpEF Summit held March 19-21, 2025, in Beverly Hills, CA.\"New treatment approaches, like Medera's gene therapy product, targeting critical pathways in the heart, are crucial for patients and caregivers faced with this difficult-to-treat disease,\" stated Marat Fudim, MD, MHS, Advanced Heart Failure Specialist and Associate Professor at Duke University Medical Center and site principal investigator. \"The encouraging early results presented at this summit reflect important progress in this critical research.\". \"We are excited to share our encouragin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medera-presented-updated-results-first-120000301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KVACW","BK4211","KVAC","HF","KVACU","SMMF"],"gpt_icon":0},{"id":"2520537314","title":"Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction","url":"https://stock-news.laohu8.com/highlight/detail?id=2520537314","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520537314?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:00","pubTimestamp":1742472000,"startTime":"0","endTime":"0","summary":"BOSTON, March 20, 2025  -- Medera Inc. , a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmetneed by developing a range of next-generation therapeutics, today announced that the independent Data and Safety Monitoring Board  has completed its planned review of the MUSIC-HFrEF Phase 1b/2 clinical trial data, recommending the completion of the Phase 1b portion and clearance to initiate the Phase 2 portion of the trial evaluating the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction .HFrEF is a prevalent form of heart disease that accounts for half of an estimated 64.3 million heart failure cases worldwide and is currently considered a mass market incurable disease.The DSMB recommendation is based on the review of data from all nine patients in the Phase 1 portion of the MUSIC-HFrEF trial, an open-label study investigating SRD-001. The Phase 1b portion included six patients in Cohort A  and three patients d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medera-receives-dsmb-clearance-initiate-120000438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KVAC","KVACU","KVACW"],"gpt_icon":0},{"id":"2518722078","title":"Medera Completes Patient Dosing for Heart Failure Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2518722078","media":"Exec Edge","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518722078?lang=en_us&edition=fundamental","pubTime":"2025-03-12 00:53","pubTimestamp":1741712010,"startTime":"0","endTime":"0","summary":"Biopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction.Additionally, Medera and Keen Vision Acquisition Corporation  announced they had entered into a definitive merger agreement on September 2024.“We are very excited and encouraged by these results, which indicate that our various new designs such as optimized dosages seem to be making differences,” said Ronald Li, Ph.D., Medera’s co-founder and CEO.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medera-completes-patient-dosing-heart-165330309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KVAC","KVACU","KVACW"],"gpt_icon":0},{"id":"2518356741","title":"Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction","url":"https://stock-news.laohu8.com/highlight/detail?id=2518356741","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518356741?lang=en_us&edition=fundamental","pubTime":"2025-03-11 21:09","pubTimestamp":1741698540,"startTime":"0","endTime":"0","summary":"BOSTON, March 11, 2025  -- Medera Inc. , a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics, today announced that patient dosing has been completed in its MUSIC-HFrEF Phase 1/2a clinical trial of the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction .HErEF is a prevalent form of heart disease that accounts for half of an estimated 64.3 million heart failure cases worldwide and is currently considered a mass market incurable disease.\"We are very excited and encouraged by these results, which indicate that our various new designs such as optimized dosages seem to be making differences,” said Ronald Li, Ph.D., CEO and co-founder of Medera.HErEF is a complex cardiovascular pathophysiological syndrome that impairs normal cardiac function and results in the inability of the heart to pump a sufficient supply of blood to meet the body","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medera-completes-patient-dosing-phase-130900041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KVACU","KVAC","KVACW"],"gpt_icon":0},{"id":"2510085452","title":"Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht","url":"https://stock-news.laohu8.com/highlight/detail?id=2510085452","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510085452?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:00","pubTimestamp":1739192400,"startTime":"0","endTime":"0","summary":"Cutting-Edge Cardiac Research: Novoheart’s CTScreen system has been installed at UMC Utrecht, equipping Regenerative Medicine Center with advanced high-throughput tools to accelerate human cardiac disease modeling and therapeutic screening, including both drug candidates and gene editing approaches. Driving Innovation: This installation paves the way for future co-development projects with UMC Utrecht, advancing human-based research and cardiac regenerative technologies. “Our team is excited to bring the CTScreensystem into our facility,” said Joost Sluijter, Ph.D., Director of the Heart and Lung Division within the Regenerative Medicine Center Utrecht. “This adds much-needed capabilities for measuring human cardiac tissue contractility, advancing our efforts in studying disease mechanisms and accelerating translation to clinical trials for patients with familial cardiomyopathies and other heart diseases that lack effective treatments.”“The installation at UMC Utrecht represents not on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medera-novoheart-expands-human-cardiac-130000920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KVACW","KVACU","KVAC"],"gpt_icon":0},{"id":"2509522743","title":"Medera, Inc. to Participate in Two Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2509522743","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509522743?lang=en_us&edition=fundamental","pubTime":"2025-02-07 21:00","pubTimestamp":1738933200,"startTime":"0","endTime":"0","summary":"SUMMIT, N.J. and BOSTON, Feb. 07, 2025  -- Medera, Inc., , a clinical-stage biotechnology company, announced today that the management team will participate in the two upcoming investor conferences in February 2025 as follows:. On September 5, 2024, Medera and Keen Vision Acquisition Corp.  announced they had entered into a definitive merger agreement.Mederais a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat or currently incurable diseases with significant unmet needs, utilizing next-generation gene and cell-based approaches in combination with bioengineered human-based technology . Medera operates via the two preclinical and clinical business units, Novoheart and Sardocor, respectively.Sardocor is dedicated to the clinical development of novel next-generation therapies for Medera. Leveraging Novoheart’s human-based drug discovery and validation platforms, Sardocor aims to expedite drug development and regulatory timelines for its gene and cell therapy","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medera-inc-participate-two-upcoming-130000616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KVACU","KVAC","KVACW"],"gpt_icon":0},{"id":"2494815194","title":"Keen Vision Acquisition Extends Business Combination Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2494815194","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494815194?lang=en_us&edition=fundamental","pubTime":"2024-12-27 06:35","pubTimestamp":1735252515,"startTime":"0","endTime":"0","summary":"Keen Vision Acquisition (KVAC) said Thursday it extended the business combination deadline to Jan. 27 after putting in a deposit.Additionally, it issued a $200,000 unsecured promissory note to the KVC","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KVACU","KVAC"],"gpt_icon":0},{"id":"2492835521","title":"Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening","url":"https://stock-news.laohu8.com/highlight/detail?id=2492835521","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492835521?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:00","pubTimestamp":1734526800,"startTime":"0","endTime":"0","summary":"Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of Novoheart’s human \"Heart-in-a-Jar\" to assess cardiac pump performance with Curi Bio’s cloud-based Pulse analytics, enabling smart and accelerated cardiac drug screening.Industry-First Capabilities Combined: Medera’s Novoheart has a unique human-based mini-Heart technology platform for disease modelling and drug screening with a track record of supporting FDA IND and FTD applications. As a pioneer in pre-clinical screening, Curi Bio has advanced cloud-based data analysis tools.Accelerated Drug Development: With newly introduced technologies, the combined platform is expected to increase efficiency, thereby reducing time and cost, increasing predictivity and empowering researchers to bring safer, more effective therapies to patients.Curi Bio brings complementary strengths with its Mantarray contractility system, Nautilai calcium imaging system, and Pulse cloud-based analytics. The Pul","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XaIQxg2jPy3sIFr3PtpWcg--~B/aD0zMjc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d02769296c6e4944d94a6996983034e4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XaIQxg2jPy3sIFr3PtpWcg--~B/aD0zMjc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d02769296c6e4944d94a6996983034e4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medera-novoheart-curi-bio-partner-130000807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KVAC","KVACW","KVACU"],"gpt_icon":0},{"id":"2490909000","title":"Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2490909000","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490909000?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:00","pubTimestamp":1733835600,"startTime":"0","endTime":"0","summary":"Innovation installed by AstraZeneca for advancing human heart-based R&D for investigational cardiovascular therapies. Features improved automation, environmental control, and flexible testing protocols, setting a new benchmark for human-based cardiac screening. CTScreen is designed to put living, bioengineered human cardiac tissue strips  that accurately mimic human heart function. This automated system can detect the effects of new treatments early in the development process, streamlining the path from discovery to clinical trials and supporting the goals of the FDA Modernization Act 2.0. This reinforces Medera’s commitment and mission to advance human-based research alternatives to animal testing, improve efficiency and success as well as reduce costs of drug development.This CTScreen v1.5 upgrade provides industry partners with powerful new tools, including automated controls, improved physiologic conditions, and versatile testing protocols that allow more sophisticated cardiac scre","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XaIQxg2jPy3sIFr3PtpWcg--~B/aD0zMjc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d02769296c6e4944d94a6996983034e4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XaIQxg2jPy3sIFr3PtpWcg--~B/aD0zMjc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d02769296c6e4944d94a6996983034e4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medera-novoheart-releases-latest-cardiac-130000039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","KVACU","IE0031619046.USD","KVAC","BK4145","KVACW","CTS"],"gpt_icon":0},{"id":"2479083670","title":"Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2479083670","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479083670?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:00","pubTimestamp":1730376000,"startTime":"0","endTime":"0","summary":"Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs. Human-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancements. This new study leverages the capabilities of artificial intelligence  and machine learning  to address the challenge of achieving automated and comprehensive \"smart\" drug screening using Medera's mini-Heart technology platform. Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates  during clinical trials, resulting in development costs that can exceed $2 billion per drug on average. Furthermore, human-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancements. Novoheart's present study demonstrates a novel approach utilizing AI/ML combined with comprehensive functional data from its various huma","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/HH0WV9SZ75gG6CKxqCwHLQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/7ec5404c07ef62a6fcfbe7e47a54ddf6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/HH0WV9SZ75gG6CKxqCwHLQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/7ec5404c07ef62a6fcfbe7e47a54ddf6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/medera-announces-publication-study-utilizing-120000500.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medera-announces-publication-study-utilizing-120000500.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4166","KVACU","KVACW","ML","KVAC"],"gpt_icon":0},{"id":"2477682115","title":"Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction","url":"https://stock-news.laohu8.com/highlight/detail?id=2477682115","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477682115?lang=en_us&edition=fundamental","pubTime":"2024-10-24 20:00","pubTimestamp":1729771200,"startTime":"0","endTime":"0","summary":"Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$100B per year. Heart failure with preserved ejection fraction  accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics. \"New treatment approaches, like Medera's gene therapy product, are critical for patients and caregivers faced with this devastating disease,\" stated Marat Fudim, MD, MHS, Advanced Heart Failure Specialist and Associate Professor at Duke University Medical Centre and site principal investigator. \"We look forward to continuing this critical research in the second cohort.\". MUSIC-HFpEF is an open-label, dose-escalation, 52-week clinical trial designed to evaluate the safety and tolerability, as well as preliminary efficacy, of SRD-002 in patients diagnosed with HFpEF. SRD-002, a gene therapy candidate utilizing an adeno-associated virus  vector carrying the cardiac isoform of the sarcoplasmic reticulum calcium ATPase pump , is adm","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QA00o9pZ2szddZztGfUUig--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/df0c99ae82f493e1556c8bb80667e767","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QA00o9pZ2szddZztGfUUig--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/df0c99ae82f493e1556c8bb80667e767"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/medera-announces-completion-cohort-initiation-120000870.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medera-announces-completion-cohort-initiation-120000870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KVACU","KVAC","KVACW","HF"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KVACU\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-07","symbol":"KVACU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741323600000,"reportTimeType":"pre","actualEps":null},{"date":"2024-11-04","symbol":"KVACU","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1730710800000,"name":null,"time":"Pre-Market","dateTimestamp":1730696400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KVACU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KVACU\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KVACU\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KVACU","date":"2025-04-22","current":16.430047,"percent":0.465854,"low":-43168.168828,"twenty":-651.628496,"median":25.162547,"eighty":32.056512,"high":140.310918,"avg":-6771.988688,"sd":13845.72571,"marketCap":121733178},"quantilePoints":[{"date":"2023-07-28","current":-34558.918444,"twenty":-34558.918444,"median":-34558.918444,"eighty":-34558.918444,"marketCap":157208520},{"date":"2023-08-04","current":-34558.918444,"twenty":-34558.918444,"median":-34558.918444,"eighty":-34524.701693,"marketCap":157208520},{"date":"2023-08-11","current":-43168.168828,"twenty":-34730.002198,"median":-34558.918444,"eighty":-34524.701693,"marketCap":196372000},{"date":"2023-08-18","current":-34802.695977,"twenty":-34837.052099,"median":-34644.460321,"eighty":-34558.918444,"marketCap":158317464},{"date":"2023-08-25","current":-34837.052099,"twenty":-34871.408222,"median":-34802.695977,"eighty":-34558.918444,"marketCap":158473750},{"date":"2023-09-01","current":-34974.476368,"twenty":-34871.408222,"median":-34837.052099,"eighty":-34558.918444,"marketCap":159098893},{"date":"2023-09-08","current":-29548.000927,"twenty":-34871.408222,"median":-34819.874038,"eighty":-34524.701693,"marketCap":159411465},{"date":"2023-09-15","current":-29634.906766,"twenty":-34871.408222,"median":-34766.349087,"eighty":-29611.731826,"marketCap":159880322},{"date":"2023-09-22","current":-36506.57683,"twenty":-34953.862695,"median":-34837.052099,"eighty":-32548.253672,"marketCap":196952982},{"date":"2023-09-29","current":-36578.369601,"twenty":-36470.68063,"median":-34837.052099,"eighty":-34511.014993,"marketCap":197340304},{"date":"2023-10-06","current":-36614.265987,"twenty":-36506.57683,"median":-34871.408222,"eighty":-34524.701693,"marketCap":197533965},{"date":"2023-10-13","current":-36793.747544,"twenty":-36542.473216,"median":-34871.408222,"eighty":-34545.231744,"marketCap":198502268},{"date":"2023-10-20","current":-36686.058573,"twenty":-36628.624467,"median":-34871.408222,"eighty":-34558.918444,"marketCap":197921286},{"date":"2023-10-27","current":-36721.954958,"twenty":-36686.058573,"median":-34940.120246,"eighty":-34558.918444,"marketCap":198114947},{"date":"2023-11-03","current":-36811.695829,"twenty":-36686.058573,"median":-36434.784244,"eighty":-34558.918444,"marketCap":198599099},{"date":"2023-11-10","current":-36865.540315,"twenty":-36722.313809,"median":-36470.68063,"eighty":-34558.918444,"marketCap":198889590},{"date":"2023-11-17","current":-36865.540315,"twenty":-36793.747544,"median":-36488.62873,"eighty":-34558.918444,"marketCap":198889590},{"date":"2023-11-24","current":-640.72649,"twenty":-36793.747544,"median":-36470.68063,"eighty":-34558.918444,"marketCap":199180081},{"date":"2023-12-01","current":-642.906892,"twenty":-36793.747544,"median":-36470.68063,"eighty":-34517.858343,"marketCap":199857894},{"date":"2023-12-08","current":-642.906892,"twenty":-36779.389064,"median":-35686.682114,"eighty":-29548.000927,"marketCap":199857894},{"date":"2023-12-15","current":-642.906892,"twenty":-36775.799444,"median":-34871.408222,"eighty":-29513.238517,"marketCap":199857894},{"date":"2023-12-22","current":-644.152834,"twenty":-36733.010936,"median":-34871.408222,"eighty":-644.02824,"marketCap":200245215},{"date":"2023-12-29","current":-643.754132,"twenty":-36722.170269,"median":-34871.408222,"eighty":-643.913613,"marketCap":200121272},{"date":"2024-01-05","current":-646.021749,"twenty":-36721.954958,"median":-34854.23016,"eighty":-644.152834,"marketCap":200826197},{"date":"2024-01-12","current":-645.579439,"twenty":-36686.058573,"median":-34837.052099,"eighty":-644.152834,"marketCap":200688698},{"date":"2024-01-19","current":-646.021749,"twenty":-36686.058573,"median":-34837.052099,"eighty":-644.152834,"marketCap":200826197},{"date":"2024-01-26","current":-647.267694,"twenty":-36686.058573,"median":-34766.349087,"eighty":-644.152834,"marketCap":201213519},{"date":"2024-02-02","current":-647.267694,"twenty":-36686.058573,"median":-34558.918444,"eighty":-644.152834,"marketCap":201213519},{"date":"2024-02-09","current":-646.021749,"twenty":-36686.058573,"median":-34558.918444,"eighty":-644.651212,"marketCap":200826197},{"date":"2024-02-16","current":-647.267694,"twenty":-36686.058573,"median":-34524.701693,"eighty":-644.775807,"marketCap":201213519},{"date":"2024-02-23","current":-646.644722,"twenty":-36686.058573,"median":-29634.906766,"eighty":-644.775807,"marketCap":201019858},{"date":"2024-03-01","current":-648.108706,"twenty":-36664.520741,"median":-29548.000927,"eighty":-645.149591,"marketCap":201474961},{"date":"2024-03-08","current":-649.759581,"twenty":-36628.624467,"median":-29519.032252,"eighty":-645.39878,"marketCap":201988162},{"date":"2024-03-15","current":-651.005523,"twenty":-36592.728155,"median":-15070.53455,"eighty":-645.507175,"marketCap":202375483},{"date":"2024-03-22","current":-651.005523,"twenty":-36578.369601,"median":-651.005523,"eighty":-645.579439,"marketCap":202375483},{"date":"2024-03-28","current":-651.628496,"twenty":-36564.011047,"median":-651.317011,"eighty":-645.579439,"marketCap":202569144},{"date":"2024-04-05","current":-652.251468,"twenty":-36542.473216,"median":-651.628496,"eighty":-645.756363,"marketCap":202762805},{"date":"2024-04-12","current":139.578745,"twenty":-36542.473216,"median":-651.005523,"eighty":-645.39878,"marketCap":203053296},{"date":"2024-04-19","current":139.778428,"twenty":-36528.114662,"median":-651.005523,"eighty":-644.402023,"marketCap":203343787},{"date":"2024-04-26","current":139.778428,"twenty":-36506.57683,"median":-650.382554,"eighty":-644.152834,"marketCap":203343787},{"date":"2024-05-03","current":139.821027,"twenty":-36506.57683,"median":-650.22681,"eighty":-643.031486,"marketCap":203405758},{"date":"2024-05-10","current":140.177795,"twenty":-36492.21835,"median":-649.759581,"eighty":-642.906892,"marketCap":203924769},{"date":"2024-05-17","current":43.198184,"twenty":-36470.68063,"median":-649.759581,"eighty":-642.906892,"marketCap":204110684},{"date":"2024-05-24","current":43.24081,"twenty":-36470.68063,"median":-649.136609,"eighty":-641.785541,"marketCap":204312091},{"date":"2024-05-31","current":43.24081,"twenty":-36470.68063,"median":-648.108706,"eighty":-640.72649,"marketCap":204312091},{"date":"2024-06-07","current":43.322783,"twenty":-36470.68063,"median":-647.890667,"eighty":43.198184,"marketCap":204699412},{"date":"2024-06-14","current":43.322783,"twenty":-36470.68063,"median":-647.890667,"eighty":43.199823,"marketCap":204699412},{"date":"2024-06-21","current":43.281796,"twenty":-36413.246413,"median":-647.734923,"eighty":43.24081,"marketCap":204505752},{"date":"2024-06-28","current":43.404756,"twenty":-36114.005561,"median":-647.423436,"eighty":43.24081,"marketCap":205086734},{"date":"2024-07-05","current":43.404756,"twenty":-34974.476368,"median":-647.267694,"eighty":43.281796,"marketCap":205086734},{"date":"2024-07-12","current":43.486729,"twenty":-34940.120246,"median":-647.267694,"eighty":43.281796,"marketCap":205474055},{"date":"2024-07-15","current":43.527716,"twenty":-34926.377841,"median":-647.267694,"eighty":43.282124,"marketCap":205667716},{"date":"2024-08-02","current":31.83307,"twenty":-34912.635436,"median":-647.267694,"eighty":43.282042,"marketCap":206926511},{"date":"2024-08-09","current":31.818174,"twenty":-34871.408222,"median":-647.267694,"eighty":43.281796,"marketCap":206829681},{"date":"2024-08-16","current":31.788382,"twenty":-34871.408222,"median":-646.644722,"eighty":43.281796,"marketCap":206636020},{"date":"2024-08-23","current":31.788382,"twenty":-34871.408222,"median":-646.644722,"eighty":43.281796,"marketCap":206636020},{"date":"2024-08-30","current":31.818174,"twenty":-34871.408222,"median":-646.644722,"eighty":43.281796,"marketCap":206829681},{"date":"2024-09-06","current":31.907551,"twenty":-34871.408222,"median":-646.333237,"eighty":43.281796,"marketCap":207410663},{"date":"2024-09-13","current":31.922447,"twenty":-34864.536997,"median":-646.021749,"eighty":43.277697,"marketCap":207507493},{"date":"2024-09-20","current":31.967135,"twenty":-34837.052099,"median":-646.021749,"eighty":43.257204,"marketCap":207797984},{"date":"2024-09-27","current":32.02672,"twenty":-34837.052099,"median":-645.579439,"eighty":43.24081,"marketCap":208185306},{"date":"2024-10-04","current":32.056512,"twenty":-34837.052099,"median":-645.39878,"eighty":43.24081,"marketCap":208378967},{"date":"2024-10-11","current":32.166744,"twenty":-34837.052099,"median":-644.775807,"eighty":43.24081,"marketCap":209095511},{"date":"2024-10-18","current":32.145889,"twenty":-34830.180875,"median":-644.152834,"eighty":43.24081,"marketCap":208959949},{"date":"2024-10-25","current":32.086305,"twenty":-34802.695977,"median":-644.152834,"eighty":43.232613,"marketCap":208572627},{"date":"2024-10-31","current":32.436364,"twenty":-34802.695977,"median":-643.641997,"eighty":43.199823,"marketCap":210848141},{"date":"2024-11-08","current":25.139398,"twenty":-34730.002198,"median":-642.906892,"eighty":43.199823,"marketCap":210315574},{"date":"2024-11-15","current":25.162547,"twenty":-34558.918444,"median":-642.906892,"eighty":43.198184,"marketCap":210509235},{"date":"2024-11-22","current":25.162547,"twenty":-34558.918444,"median":-642.906892,"eighty":43.198184,"marketCap":210509235},{"date":"2024-11-29","current":25.231992,"twenty":-34558.918444,"median":-642.906892,"eighty":43.198184,"marketCap":211090217},{"date":"2024-12-06","current":25.255141,"twenty":-34558.918444,"median":-642.28392,"eighty":34.588728,"marketCap":211283878},{"date":"2024-12-13","current":25.301438,"twenty":-34558.918444,"median":-641.660947,"eighty":32.418489,"marketCap":211671199},{"date":"2024-12-20","current":25.324587,"twenty":-34531.545043,"median":-640.72649,"eighty":32.318685,"marketCap":211864860},{"date":"2024-12-27","current":25.347735,"twenty":-34524.701693,"median":-640.570747,"eighty":32.22335,"marketCap":212058521},{"date":"2025-01-03","current":25.44033,"twenty":-34511.014993,"median":25.139398,"eighty":32.172107,"marketCap":212833164},{"date":"2025-01-10","current":25.463479,"twenty":-33519.369307,"median":25.150973,"eighty":32.162573,"marketCap":213026825},{"date":"2025-01-17","current":25.463479,"twenty":-29623.319296,"median":25.162547,"eighty":32.14291,"marketCap":213026825},{"date":"2025-01-24","current":25.532924,"twenty":-29576.969416,"median":25.162547,"eighty":32.130993,"marketCap":213607807},{"date":"2025-01-31","current":25.648667,"twenty":-29548.000927,"median":25.162547,"eighty":32.086603,"marketCap":214576111},{"date":"2025-02-07","current":25.718113,"twenty":-29548.000927,"median":25.162547,"eighty":32.086603,"marketCap":215157093},{"date":"2025-02-14","current":25.741262,"twenty":-29548.000927,"median":25.162547,"eighty":32.086305,"marketCap":215350754},{"date":"2025-02-21","current":25.76441,"twenty":-29524.825987,"median":25.174121,"eighty":32.086305,"marketCap":215544414},{"date":"2025-02-28","current":25.810708,"twenty":-29519.032252,"median":25.231992,"eighty":32.086305,"marketCap":215931736},{"date":"2025-03-07","current":25.810708,"twenty":-29495.857312,"median":25.255141,"eighty":32.086305,"marketCap":215931736},{"date":"2025-03-14","current":29.222224,"twenty":-6419.81389,"median":25.255141,"eighty":32.086305,"marketCap":216512718},{"date":"2025-03-21","current":16.320514,"twenty":-652.251468,"median":25.255141,"eighty":32.086305,"marketCap":120921624},{"date":"2025-03-28","current":16.415443,"twenty":-652.251468,"median":25.231992,"eighty":32.086305,"marketCap":121624971},{"date":"2025-04-04","current":16.34242,"twenty":-652.251468,"median":25.174121,"eighty":32.086305,"marketCap":121083935},{"date":"2025-04-11","current":16.386234,"twenty":-652.002278,"median":25.162547,"eighty":32.062471,"marketCap":121408556},{"date":"2025-04-17","current":16.430047,"twenty":-651.75309,"median":25.162547,"eighty":32.056512,"marketCap":121733178},{"date":"2025-04-22","current":16.430047,"twenty":-651.628496,"median":25.162547,"eighty":32.056512,"marketCap":121733178}],"updateTime":1745411795007}}}